Altria
MO
$69.24
+0.86%
Altria Group, Inc. is a leading tobacco company in the United States, operating through subsidiaries that produce and market cigarettes, smokeless tobacco, and cigars, with its flagship Marlboro brand holding a dominant 40% market share. The company is a mature market leader in a declining industry, distinct for its immense cash-generating ability, high dividend yield, and strategic investments in adjacent categories like cannabis (Cronos) and reduced-risk products (NJOY vaping, heated tobacco). The current investor narrative centers on the sustainability of its generous dividend amidst secular declines in cigarette volumes, the progress of its smoke-free product portfolio to offset legacy declines, and debates over whether its valuation already prices in terminal decline or offers a compelling value and income opportunity.…
MO
Altria
$69.24
Related headlines
Investment Opinion: Should I buy MO Today?
Rating & Thesis: Hold. Altria is a high-yield, low-growth defensive stock suitable for income-focused portfolios, but its secular headwinds and full valuation near 52-week highs limit near-term upside. The mixed analyst sentiment, with recent upgrades to 'Buy' but also 'Underweight' ratings, reflects this balanced, cautious view.
Supporting Evidence: The primary valuation metric, a forward P/E of 11.85x, is below typical tobacco multiples, suggesting value. The 7.20% dividend yield is exceptionally high and supported by $9.07B in TTM free cash flow. Profitability remains strong with a 34.50% TTM net margin. However, the stock trades at 93.3% of its 52-week range, indicating limited near-term margin of safety after a 16.98% annual run-up.
Risks & Conditions: The two biggest risks are a faster-than-expected decline in cigarette cash flows and a dividend cut triggered by payout unsustainability. This Hold rating would upgrade to Buy if the price pulls back meaningfully below $65 (offering a higher yield and better entry) or if smoke-free product revenue demonstrates accelerating, profitable growth. It would downgrade to Sell if quarterly free cash flow shows a sustained sequential decline or if the dividend payout ratio climbs further above 110%. The stock is currently fairly valued relative to its challenged growth profile but appears slightly overextended on a technical basis after its recent rally.
Sign up to view all
MO 12-Month Price Forecast
Altria's investment case is a trade-off between high current income and long-term terminal decline. The neutral stance reflects a view that the stock is fairly valued after its recent run-up, with the generous yield offsetting the lack of growth. The base case (60% probability) of range-bound trading is most likely, as the company's massive cash flows are predictable in the near term. The stance would turn bullish on a significant price pullback that boosts the yield above 8% or on clear evidence that smoke-free products are becoming a meaningful profit contributor. It would turn bearish on any indication of a dividend cut or a sustained breakdown below the $65 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Altria's 12-month outlook, with a consensus price target around $90.01 and implied upside of +30.0% versus the current price.
Average Target
$90.01
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$55 - $90
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this large-cap stock has lower institutional coverage than peers, which can contribute to valuation inefficiency. The consensus sentiment appears mixed, as institutional ratings show a recent upgrade from UBS to 'Buy' in January 2026 but also maintain 'Underweight' and 'Neutral' stances from others, reflecting the debate between its high yield and growth challenges. The target price range is implied through earnings estimates, with an average EPS estimate of $6.39 for the next period, but without explicit price targets provided, the implied upside cannot be calculated; the wide dispersion in historical P/Es suggests analyst targets would also show a broad range, signaling high uncertainty around the appropriate multiple for the stock's future cash flows.
Bulls vs Bears: MO Investment Factors
The bull case for Altria rests on its formidable cash generation, high dividend yield, and defensive characteristics, which are currently validated by a 17% annual price gain and trading near 52-week highs. The bear case is anchored in the inexorable secular decline of its core business and the uncertain, slow progress of its growth initiatives. The evidence currently leans slightly bullish for income and value investors, given the compelling yield and discounted valuation (11.85x forward P/E). The single most important tension in the investment debate is the race between the pace of cash flow decay from cigarettes and the success (and eventual profitability) of its smoke-free product portfolio. The resolution of this tension will ultimately determine whether the stock is a value trap or a successful income compounder.
Bullish
- Exceptional Dividend Yield & Cash Flow: The stock offers a 7.20% dividend yield, funded by robust TTM free cash flow of $9.07 billion. This high yield provides a significant income cushion and is a primary attraction for income-focused investors in a low-growth environment.
- Strong Profitability & Pricing Power: Altria maintains high gross margins of 62.11% (Q4) and a TTM net margin of 34.50%, demonstrating its pricing power and brand strength despite volume declines. The forward P/E of 11.85x is below the typical tobacco sector multiple, suggesting value.
- Dominant Market Position: The company's Marlboro brand holds a commanding 40% share of the US cigarette market, providing a stable, albeit declining, cash cow. This entrenched position supports consistent pricing and cash generation.
- Strategic Investments for Transition: Investments in reduced-risk products like NJOY vaping and Cronos cannabis represent a strategic, albeit early-stage, effort to offset legacy declines. These provide optionality for future growth beyond cigarettes.
Bearish
- Secular Decline in Core Business: The company is a leader in a structurally declining industry, with cigarette volumes under persistent pressure. Revenue growth is volatile (14.49% YoY in Q4, but lumpy quarterly), and long-term sustainability depends on a shrinking customer base.
- Smoke-Free Transition Struggles: Progress in smoke-free products (e.g., vaping, heated tobacco) remains slow and faces intense regulatory and competitive hurdles. The Smokeless Products segment revenue of $706M in Q4 is still dwarfed by the $5.12B Smokeable segment, highlighting the transition challenge.
- Financial Statement Distortions: Aggressive buybacks have led to a negative book equity, resulting in a negative ROE of -198.37% and a negative D/E ratio of -7.34. While an accounting artifact, it complicates traditional financial health analysis and signals a capital return policy that may not be sustainable indefinitely.
- Limited Liquidity & High Payout: A current ratio of 0.61 indicates potential short-term liquidity constraints. The dividend payout ratio of over 100% (1.0019) suggests the dividend is not fully covered by earnings, raising questions about its long-term security if cash flow weakens.
MO Technical Analysis
The stock is in a sustained uptrend, having gained 16.98% over the past year and trading near the top of its 52-week range, specifically at 93.3% of the range between its 52-week low of $54.70 and high of $74.56, indicating strong momentum but also potential overextension. Recent momentum shows acceleration, with the stock up 2.02% over the past month and 0.78% over the past three months, though these gains significantly lag the broader market, as evidenced by relative strength figures of -4.29 and -9.50 against the SPY, suggesting the uptrend is driven by stock-specific factors rather than beta. Key technical levels are clear, with immediate resistance at the 52-week high of $74.56 and support at the 52-week low of $54.70; a breakout above resistance would signal a new bullish phase, while a breakdown below support would invalidate the uptrend, and the stock's low beta of 0.519 indicates it is roughly half as volatile as the market, which is typical for a defensive consumer staple.
Beta
0.52
0.52x market volatility
Max Drawdown
-19.1%
Largest decline past year
52-Week Range
$55-$75
Price range past year
Annual Return
+14.2%
Cumulative gain past year
| Period | MO Return | S&P 500 |
|---|---|---|
| 1m | -7.1% | +5.4% |
| 3m | +1.6% | +10.9% |
| 6m | +18.7% | +11.0% |
| 1y | +14.2% | +28.1% |
| ytd | +20.8% | +11.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MO Fundamental Analysis
Revenue growth is modest and volatile on a quarterly basis; the most recent Q4 2025 revenue was $5.85 billion, representing a 14.49% year-over-year increase, but this follows a Q3 where revenue was $5.25 billion, indicating lumpy performance, with the Smokeable Products segment ($5.12B) remaining the dominant driver while Smokeless Products ($706M) provides a smaller growth avenue. Profitability remains robust with a net income of $1.12 billion in Q4 and a high gross margin of 62.11%, though net margin of 19.11% in that quarter is below the trailing twelve-month net margin of 34.50%, reflecting potential quarterly volatility in earnings; the company is consistently profitable with strong operating leverage. The balance sheet and cash flow are hallmarks of the investment case, with substantial free cash flow of $9.07 billion (TTM) funding a high dividend yield of 7.20%, though financial health is complicated by a negative debt-to-equity ratio of -7.34 and a negative return on equity of -198.37%, which are accounting artifacts likely due to significant shareholder buybacks reducing book equity, while a current ratio of 0.61 indicates limited short-term liquidity.
Quarterly Revenue
$5.8B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MO Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 13.92x, while the forward P/E is lower at 11.85x, indicating the market expects earnings growth or a normalization from recent quarterly volatility. Compared to sector averages, Altria's trailing P/E of 13.92x trades at a discount to the typical tobacco/consumer staple multiple, which often ranges in the mid-to-high teens, a discount justified by its exposure to secular decline in cigarettes and slower transition to smoke-free products. Historically, the stock's own P/E has fluctuated significantly, with recent quarterly historical ratios showing figures as high as 81x and as low as 5.2x over the past few years; the current 13.92x sits below the multi-year average, suggesting the stock is not at peak valuation and may offer value if earnings stabilize.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -8x~81x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the sustainability of the dividend and capital structure. The dividend payout ratio exceeds 100%, indicating it is funded by more than just current earnings, relying on strong free cash flow. A negative book equity and ROE, resulting from massive share buybacks, mask traditional leverage metrics but indicate a policy that may be difficult to maintain if cash flows decline. Furthermore, quarterly earnings volatility is high, as seen in the drop from a 34.50% TTM net margin to a 19.11% Q4 margin, introducing uncertainty into income projections.
Market & Competitive Risks are dominated by the secular decline in tobacco consumption and regulatory pressures. The stock trades at a forward P/E of 11.85x, a discount to sector peers, but this discount is justified by its lack of growth and transition challenges. Its low beta of 0.519 offers defensive appeal but also means it will likely lag in strong bull markets, as evidenced by its significant negative relative strength versus the SPY over 1-month (-4.29) and 3-month (-9.50) periods. Competitive and regulatory risks to its NJOY and heated tobacco ventures threaten its long-term repositioning strategy.
The Worst-Case Scenario involves an acceleration of cigarette volume declines coupled with regulatory setbacks for reduced-risk products, leading to a sustained drop in cash flow. This could force a dividend cut, breaking the core investment thesis and triggering a severe derating. The realistic downside is anchored by the 52-week low of $54.70, which represents a potential decline of approximately -21% from the current price of $69.58. A reversion to the lower end of its historical P/E range could see the stock test or break below this level, with losses potentially exceeding 25% in a prolonged adverse scenario.
FAQ
The key risks are: 1) Secular Decline Risk: The core cigarette business is in permanent structural decline, threatening long-term cash flows. 2) Dividend Sustainability Risk: The payout ratio exceeds 100%, and a sustained cash flow drop could force a cut, devastating the stock price. 3) Transition Execution Risk: The company's investments in vaping (NJOY) and cannabis (Cronos) may fail to offset legacy declines due to competition and regulation. 4) Financial Structure Risk: Negative book equity and a low current ratio of 0.61 complicate the financial health picture and limit flexibility.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $65 and $74, as it maintains its dividend and executes its slow transition plan. The Bull Case (25% probability) targets $74.56 to $82, driven by successful smoke-free product growth and multiple expansion. The Bear Case (15% probability) sees a drop to the $54.70 - $60 range if dividend fears materialize or volumes decline sharply. The Base Case is most likely, implying limited upside from the current ~$69.58 price but a high yield for compensation.
MO appears fairly valued to slightly overextended. Its forward P/E of 11.85x is below the typical tobacco sector multiple, suggesting it is not overvalued on an earnings basis. However, the stock trades at 93.3% of its 52-week range after a significant rally, indicating it is priced for near-perfection. The market is paying a fair price for a stream of cash flows that is expected to slowly decline, with a discount applied for that terminal risk. It is not clearly undervalued at current levels.
MO is a good buy for a specific type of investor: those seeking high current income and defensive exposure, and who are comfortable with the long-term secular risks of the tobacco industry. The 7.20% dividend yield is compelling and supported by strong cash flow. However, after a 17% annual gain, the stock trades near its 52-week high, offering limited margin of safety. For growth-oriented investors or those with a short time horizon, it is not a good buy. For income investors, it may be prudent to wait for a pullback to a lower price point to lock in a higher yield.
MO is suitable primarily for long-term, income-oriented investment. Its low beta of 0.519 and high dividend are designed for compounding income over years, not short-term trading gains. The secular challenges require a long horizon to collect the dividend while the company navigates its transition. Short-term trading is complicated by low volatility and the stock's tendency to move on dividend-related news rather than rapid growth catalysts. A minimum holding period of 3-5 years is suggested to realize the benefits of the income stream and navigate cyclical volatility.